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ABSTRACT
Objective: This study was aimed to develop a tool for the
standardized assessment of patient-reported outcomes
(PROs) to assist the choice of instruments.
Methods: An expert panel adapted the eight attributes pro-
posed by the Medical Outcomes Trust as evaluation review
criteria, created items to evaluate them, and included a
response scale for each item. A pilot test was designed to test
the new tool’s feasibility and to obtain preliminary informa-
tion concerning its psychometric properties. The Spanish ver-
sions of ﬁve measures were selected for assessment: the SF-36
Health Survey, the Nottingham Health Proﬁle, the COOP-
WONCA charts, the EuroQol-5D, and the Quality of Life
Questionnaire EORTC-QLQ-C30. We assessed the new
tool’s reliability (Cronbach’s alpha and intraclass correlation
coefﬁcient [ICC]) and construct validity.
Results: The new EMPRO (Evaluating the Measurement of
Patient-Reported Outcomes) tool has 39 items covering
eight key attributes: conceptual and measurement model,
reliability, validity, responsiveness, interpretability, burden,
alternative modes of administration, and cross-cultural
and linguistic adaptations. Internal consistency was high
(a = 0.95) as was interrater concordance (ICC: 0.87–0.94).
Positive associations consistent with a priori hypotheses
were observed between EMPRO attribute scores and the
number of articles identiﬁed for the measures, the years
elapsed since the publication of the ﬁrst article, and the
number of citations.
Conclusion: A new tool for the standardized assessment of
PRO measures is available. It has shown good preliminary
reliability and validity and should be a useful aid to investi-
gators who need to choose between alternative measures.
Further assessment of the tool is necessary.
Keywords: assessment, health-related quality of life, patient-
reported outcomes, psychometric properties.
Introduction
The search for health outcome measures that incorpo-
rate the patient’s perspective has led to the production
of an increasing number of “patient-reported out-
come” (PRO) measures [1,2]. This has been in part due
to new models of care with greater patient involve-
ment in decision-making, as well as the recognition
that these measures can independently predict the use
of health services, such as hospitalization, primary
care, health-care needs, and even mortality [3,4]. They
also elicit information which has found to be comple-
mentary to commonly used clinical measures [5].
Recent estimates, based solely on publications in
English, place the number of measures at 1275 [6].
This poses at least two problems: 1) how to identify
questionnaires which are available for a speciﬁc use
(e.g., a study of functional status in patients with
asthma); and 2) how to choose the most appropriate
measure from among those available. Some initiatives
have addressed the ﬁrst of these problems by compiling
catalogues of questionnaires in different formats
(including books and electronic databases) [7–12].
As regards the second question, criteria are needed
to identify the strengths and weaknesses of the PRO
measures. These criteria should cover the conceptual
and theoretical model on which the measure is based,
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as well as its psychometric properties (reliability,
validity, or sensitivity to change). Several attempts
have been made to systemize review criteria for PRO
measures, all of which are inspired by the seminal
work of McDowell et al. [7]. Several attempts have
been made to systematize review criteria for PRO
measures. The GraQol Index was the ﬁrst attempt
to develop a tool that generated a global score [13].
Although promising, the authors recognized several
limitations in the evaluation of speciﬁc attributes and
criteria selected which limited its use [13]. The major-
ity of other initiatives have not transcended the use
they were originally designed for with one possible
exception, namely the proposal by the Scientiﬁc
Advisory Committee of the Medical Outcomes Trust
(MOT). The MOT is a nonproﬁt organization in the
United States, which aims to provide quality control
guidelines for the development of measures that incor-
porate the patient’s perspective in the ﬁeld of health
service research [14]. Based initially on sound theoreti-
cal grounds, the MOT initiative was recently expanded
to include an explicit guide as to how each criterion
should be met [15].
The aims of the present study were to apply these
recent advances to develop a tool for the standardized
assessment of PRO measures and to obtain prelimi-
nary information on its validity and reliability.
Methods
The Spanish Cooperative Investigation Network for
Health and Health Service Outcomes Research (Red-
IRYSS) was established in 2002 and had as one of its
main goals the promotion of health-related quality of
life measures for use with Spanish-speaking popula-
tions [16]. As it was considered that one way of achiev-
ing this aim would be to have a tool available
for the standardized assessment of PRO measures,
members of the Red IRYSS reviewed earlier initiatives
to produce such a tool. After review, the updated
version of the MOT proposal was selected as provid-
ing the most comprehensive and explicit set of re-
commendations available [15]. This proposal is the
broadest in scope in terms of the attributes assessed, as
it includes the psychometric characteristics of the ques-
tionnaires as well as the administration procedures; it
also provides the most thorough speciﬁcation of crite-
ria that need to be met by PRO measures.
Development
As a ﬁrst step in the development of the new tool, a
panel of four experts was nominated, based on their
substantive experience in the development, assessment,
and use of PRO measures (see Acknowledgments for
the members of the panel). The panel operatively
deﬁned the quality of a PRO instrument as the “degree
of conﬁdence that all possible bias has been minimized
and that the information about the process which led to
its development and evaluation is clear and accessible.”
The content of the new tool was generated by con-
verting each of the speciﬁc criteria in the MOT pro-
posal into individual items. The expert panel aimed to
respect the original wording as far as possible and
to maximize standardization of the assessment-
incorporated quantitative criteria based on the litera-
ture whenever possible [14–18].
The format of the instrument (response options
and structure) was based on the AGREE (Appraisal
of Guidelines Research and Evaluation) instrument, a
tool originally conceived for the appraisal of clinical
practice guidelines [19]. This instrument has been
shown to have excellent properties, and it has been
widely disseminated [19–22].
The resulting tool was then circulated to other
researchers for their views on the clarity of its content,
comprehensiveness, and ease of use (see Acknowledg-
ments). A ﬁnal version was obtained which incorpo-
rated their suggestions, and a user’s manual was
produced.
Assessment Process
Once the tool was created, the expert panel deﬁned
the process to be followed when evaluating a PRO
measure, consisting on the assessment by several
reviewers of standardized information retrieved for
each PRO measure.
Evaluation of Psychometric Properties
A pilot study was performed to test the new tool’s
feasibility of use and measurement properties (score
distributions, reliability, and validity). The measures
assessed were the Spanish versions of ﬁve well-known
and widely used PRO instruments. These included four
commonly used generic questionnaires [6] (the SF-36
Health Survey [23,24], the Nottingham Health Proﬁle
[25,26], the COOP-WONCA Charts [27,28], and the
EuroQol-5D [29,30]), and an instrument used in
patients with cancer (the Quality of Life Questionnaire
EORTC-QLQ-C30 [31,32]).
Twenty reviewers were invited to participate based
on their experience in using and evaluating PRO mea-
sures. Only one reviewer declined to participate. All
but four reviewers were members of the Scientiﬁc
Committee on “Patient-Reported Outcomes” of the
IRYSS Network. The others were external researchers
without any formal link to the project. Five panels
were formed to review the selected instruments: four
panels had four reviewers each and one panel had
three reviewers. The four member panels each included
one of the external reviewers. Each panel was assigned
one of the selected instruments to assess. Within each
panel, instruments were assessed independently by the
reviewers; reviewers had not been involved in the
development or adaptation of the instrument assigned.
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In order to complete the assessment, each reviewer
was provided with the new tool, together with the
following documents:
• The original and Spanish versions of the instru-
ment to be assessed;
• The user manual for the Spanish version;
• Related full-text publications (articles, conference
papers, information provided by the authors and
other documents), which provided information
concerning the adaptation into Spanish;
• An article describing the conceptual model of the
original questionnaire (not the Spanish version);
• Publications on the validation of the Spanish
version and other information related to psycho-
metric properties; and
• A list of all the references identiﬁed related to
applications of the questionnaire (with summaries
when available).
All these documents were identiﬁed through a system-
atic review performed for each questionnaire [33].
Selected databases included PubMed [34,35], ISI Web
of Knowledge [36], ProQOLID [37], as well as the
Iberoamerican bibliographic databases LILACS [38]
and SCIELO [39], and local databases of Spanish
biomedical literature, including databases of doctoral
theses [40–43]. Speciﬁc search deﬁnitions for each
database are available from the authors upon request.
Nonelectronic sources were also searched [6,8–12,44].
All searches were performed between April and June
2004.
The documentation was made available to review-
ers both on a CD-ROM and on a secure web site with
password-protected access. Materials also included
written instructions on the assessment procedure and
reviewers were asked to complete the review within
30 days.
Analytic Strategy
In order to assess the feasibility of EMPRO, the pro-
portion of assessments that were returned within the
established time period and the number of missing
values per assessment was determined. Floor and
ceiling effects were calculated for each attribute as the
percentage of assessments with the minimum (ﬂoor)
and maximum (ceiling) scores [45].
Reliability was assessed by examining internal con-
sistency and reproducibility [46]. Internal consistency
was calculated using Cronbach’s alpha coefﬁcient for
each attribute in each panel, and a global estimate in
each panel was also obtained (median). Reproducibil-
ity was measured as interrater concordance on
attribute scores and was assessed using the intraclass
correlation coefﬁcient (ICC) for random effects in each
panel (two-way model, absolute agreement) [47]. In
order to determine whether being an external reviewer
affected the assessment, we performed face-to-face
comparisons for all reviewer pairs in each panel
including external reviewers (ICC). For all reliability
measurements, values greater than 0.7 were considered
acceptable, and values greater than 0.9 were consid-
ered highly satisfactory [17].
A priori hypotheses were formulated with regard to
construct validity. We hypothesized that instrument
quality would be related to the quality of the publica-
tions featuring the instrument. The rationale was that
studies describing well-developed, thoroughly tested
instruments would have a greater chance of being pub-
lished in higher-quality publications. The quality of the
related publications was deﬁned in terms of selected
bibliometric characteristics, namely: 1) absolute num-
ber of publications; and 2) citations referring to the
ﬁrst publication (ISI Journal Citation Reports) [48].
The time the instrument had been available (number of
years elapsed since the publication of the ﬁrst article)
was also taken into account to determine its effect on
the assessment. The Spearman correlation coefﬁcient
was used to measure the association between these
variables and the attribute scores [49]. Given the small
sample of measures (n = 5), emphasis was placed on
direction of the associations observed rather than
statistical signiﬁcance. All analyses were carried out
using the R software (R Foundation for Statistical
Computing, Vienna, Austria) [50].
Results
The EMPRO Tool
The new tool consisted of 39 items organized in eight
attributes: Conceptual and measurement model (7
items); Reliability (8); Validity (6); Responsiveness (3);
Interpretability (3); Administration burden (7); Alter-
native modes of administration (2); and Cross-cultural
and linguistic adaptations (3). Each item consisted of a
statement together with a short text to help in its
interpretation and application. Reviewers expressed
their degree of agreement with the statement on an
ordinal Likert-type response scale: “Strongly agree”
(4), “Agree” (3), “Disagree” (2), and “Strongly dis-
agree” (1). Space was provided on each item for
comments and references to relevant publications or
documents.
At the end of the instrument, reviewers were
requested to provide an overall recommendation
for the measure and provide a rationale for their
recommendation. Possible choices were: “Strongly
recommended,” “Recommended with provisos or
alterations,” “Would not recommend,” and “Unsure.”
Scores were assigned based on attribute scores, as
well as on the overall degree of recommendation.
Attribute scores were calculated as the mean of the
responses to all items for that attribute, with a lineal
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transformation to obtain the scores on a scale from 0
(minimum) to 100 (maximum).
The new tool was named EMPRO (Evaluating
the Measurement of Patient-Reported Outcomes).
Examples of item structure and overall ratings are
shown in Figures 1 and 2, respectively. Full content is
available in Appendix 1 (Supplementary material).
Pilot Test
Materials for the evaluation of selected measures. The
questionnaire-speciﬁc systematic reviews identiﬁed a
variable number of articles, ranging from 6 to 18. All
of the articles detailing the conceptual model of the
original version of the questionnaire (n = 5, one per
questionnaire) and most of those reporting the adap-
tation into Spanish were published in international
journals (median proportion of international publica-
tions = 67%, range from 20% to 80%). The number
of citations for the ﬁrst reference reporting the cultural
adaptation ranged from 133 to 0. A user manual was
identiﬁed for all of the instruments.
Feasibility. All assessments were carried out within the
required time period (1 month) and there were no
missing data. Nine reviewers (47.4%) completed a
questionnaire on the documentation provided, and all
found the documentation “Relevant” or “Very rel-
evant” and the selection of materials “Quite appropri-
ate” or “Very appropriate.” One reviewer considered
the information “Insufﬁcient.”
Attribute scores for individual reviewers ranged
from 22 to 100 (median scores ranged from 25 to 100)
(Table 1). No ﬂoor effect was therefore observed.
Three attributes (Reliablity, Validity, and Responsive-
ness) did not receive the maximum score (100) on any
of their individual items. A ceiling effect was observed
for the attributes of cross-cultural and linguistic adap-
tations (36.8%) and Interpretability (15.8%).
Reliability and validity. As regards internal consis-
tency, Cronbach alpha coefﬁcients were above 0.7 for
all attributes (Table 1). Internal consistency was very
high when calculated for all EMPRO items as a whole
(median a = 0.95). The degree of agreement was
1. The concept to be measured is clearly stated. 
Aspects to be considered: 
- The broad concept the instrument is trying to measure (e.g., functional 
status, well-being, health-related quality of life, satisfaction, etc.) is 
clearly stated.
- If the instrument is designed to assess multiple domains, a listing of all 
the domains or dimensions is provided. 
  1 2 3 4 
Strongly Agree        Strongly Disagree 
Reference: Comments:
Figure 1 Sample item from the EMPRO tool.
OVERALL ASSESSMENT
Considering the information available, how would you rate use of  this instrument for 
the analysis of health status and services outcomes? 
 1 Strongly recommended 
 2 Recommended (with provisos or alterations) 
 3 Would not recommend 
 4 Unsure 
Comments:
Figure 2 Overall degree of recommendation.
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similar between members of the scientiﬁc committee
and external assessors and members of the scientiﬁc
committee (data not shown). We also explored the
effect of the availability of information on agreement
(ICC): no correlation was found between the degree of
concordance and the number of articles published
(Spearman Rho = -0.05, P = 0.93), but a correlation
was found between the degree of concordance and
years elapsed since the publication of the ﬁrst article
about the adapted version (Spearman Rho = 0.89,
P < 0.05).
Positive associations consistent with our a priori
hypotheses were observed between EMPRO attribute
scores and the number of articles identiﬁed for each
questionnaires and the number of citations (Table 2).
The only exceptions were correlation coefﬁcients close
to 0 between scores on the attribute of “Responsive-
ness” and number of articles, and between “Adminis-
trative Burden” and the number of citations. The
overall recommendations also showed the expected
associations. All correlations observed between years
elapsed since the publication of the ﬁrst article and
EMPRO scores were positive.
Discussion
A new tool has been developed, based on earlier
explicit recommendations, to aid in the standardized
assessment of PRO measures. It has been successfully
used to evaluate the Spanish versions of ﬁve well-
known PRO measures, and the results of the pilot
study suggest that it is feasible to use and provide
preliminary evidence of its psychometric properties.
The study had a number of limitations. First, the
results are based on a small number of reviewers and
instruments. Although we did not observe any sub-
stantial departure of the assumptions for the calcula-
tion of the indices and statistical tests in our study,
further replication of our methods in larger samples is
necessary. Second, the measures used to evaluate
EMPRO’s psychometric properties were Spanish ver-
sions. It is likely that the retrieval of information for
the original instruments would have resulted in an
increased number of publications. Nevertheless, it is
possible that EMPRO’s performance would improve
with an increase in the amount and quality of infor-
mation available for the measures assessed. Third, the
assessment of the construct validity for this new tool
is still tentative. The bibliometric criteria and their
hypothesized associations with the scores were proxies
of scientiﬁc quality, and they may therefore not repre-
sent the quality of a particular manuscript. Fourth,
although we asked some researchers about their views
on clarity, comprehensiveness, relevance, and ease of
use of the tool, we did not perform a formal cognitive
pretest before this pilot testing. Nonetheless, agree-
ment regarding the quality of the measures assessedTa
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was high among reviewers, thereby suggesting that the
items were actually understood in a similar way by the
respondents.
Characteristics of the EMPRO Tool
The values obtained for internal consistency can be
considered satisfactory, with all attributes reaching 0.7
and four of them (50%) with coefﬁcients of 0.8 or
higher. As reliability depends on the number of items
and observations (in part), further studies should
include a larger number of measures, and alternative
approaches using modern test theory could be applied
[51]. The observed level of interrater agreement can
also be considered very satisfactory.
Our data also suggest that the EMPRO tool is valid.
The method used to develop the instrument supports
its content validity, and as a matter of fact the MOT
proposal has been very recently used in a similar ini-
tiative [52]. The expected associations were observed
between EMPRO scores and the variables proposed,
supporting the construct validity of the tool. Neverthe-
less, these relations are also consistent with the
hypothesis that EMPRO scores depend on the quantity
and quality of the information provided for the assess-
ment. The correlation found between the scores
and the information provided (quantity and quality)
stresses the need for the information to be identiﬁed by
means of standardized procedures (systematic review)
and be subsequently organized according to explicit
criteria.
It was not possible to evaluate the responsiveness of
the new tool in the present study. This could be linked
to the availability of new information concerning ques-
tionnaires that have previously been assessed, based on
either new articles, conference papers, or information
provided directly by the author.
Applicability
The availability of an instrument to assess the psycho-
metric characteristics and ease of use of PRO measures
entails a signiﬁcant advantage for diverse ﬁelds of
application, such as clinical, administrative, and
research applications. The diversity of existing ques-
tionnaires and their relatively recent development
make it difﬁcult to identify the most appropriate one
for a given use such as monitoring patients in clinical
practice [53], identifying population preferences, or
choosing the most appropriate questionnaire to evalu-
ate the effect of a therapeutic intervention in a clinical
trial. The lack of success of previously developed
assessment tools is due largely to the fact that they
were developed for use within speciﬁc contexts, such
as in compilations of PRO questionnaires, and there-
fore, with rare exceptions, have not been disseminated
independently. The instrument we propose has the
advantage that it has been developed based on the
updated recommendations of experts and that it
explicitly speciﬁes review criteria. Researchers will also
ﬁnd in EMPRO a powerful tool in their practice, par-
ticularly when considering recent FDA guidance which
has established an iterative PRO Instrument Develop-
ment and Modiﬁcation Process that explicitly recog-
nizes the assessment of measurement properties as a
key step in the reﬁnement of the instruments [54].
Speciﬁcally, each of the four measurement properties
that the FDA guidance recommend to review (reliabil-
ity, validity, ability to detect change, and choice of
methods for interpretation) corresponds to one of the
EMPRO attributes.
Four considerations are worth making for future
users of the tool. First, the EMPRO tool relies com-
pletely on information obtained in studies in which the
instruments are assessed within a speciﬁc application.
Second, overall ratings and attribute scores are con-
ceptually different measures which are not intended to
be interchangeable. The latter are based on the appli-
cation of explicit criteria, while the overall ratings
involve making a subjective recommendation for
the instrument given the speciﬁc purposes (concept
and populations) it was designed for. Both measures
provide relevant complementary information that
should be considered together when comparing ques-
Table 2 Construct validity: correlations (Spearman Rho) between EMPRO median attribute scores and selected bibliometric char-
acteristics of the measures
EMPRO attributes No. of articles† Years elapsed‡ JCR citations‡
Conceptual and measurement model 0.79 0.45 0.87
Reliability 0.26 0.45 0.72
Validity 0.89* 0.80 0.63
Responsiveness 0.05 0.89* 0.36
Interpretability 0.97* 0.57 0.63
Administrative burden 0.53 0.22 -0.15
Alternative modes of administration 0.97* 0.57 0.58
Cross-cultural and linguistic adaptations 0.97* 0.34 0.63
Overall recommendation 0.56 0.79 0.54
*P < 0.05.
†Number of articles identiﬁed concerning the development/adaptation of the Spanish version of the questionnaire.
‡Years elapsed and citations for the ﬁrst publication only.
EMPRO, Evaluating the Measurement of Patient-Reported Outcomes; JCR, Journal Citation Reports.
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tionnaires. Third, given the lack of experience with this
newly available tool, explicit guides to interpretation
have not yet been developed. Available scores for
ﬁve of the most widely used instruments might prove
a useful starting point. Fourth, the choice of any
measure will depend on the intended use. In this
context, the assessment with EMPRO of several com-
peting PRO questionnaires could help potential users
to identify those meeting minimal criteria to be
included in the selection. Furthermore, some attributes
could assist the choice of the most suitable measure for
a speciﬁc application. For example, information on
responsiveness will be particularly relevant for longi-
tudinal studies designed to evaluate therapeutic inter-
ventions, while administrative burden might be of
particular relevance if measures are to be used in
quality programs within health-care delivery systems.
Finally, the application of EMPRO assumes expert
knowledge in the use and assessment of PRO mea-
sures. Although it is true that the instrument includes a
basic guide to the main concepts, reviewers need a
minimum level of knowledge to guarantee interrater
concordance. A set of training materials to prepare
people who will use EMPRO is currently being devel-
oped. Moreover, given the learning curve, it is not
unreasonable to expect that interrater concordance
would increase if the same reviewers reassessed the
same instruments using EMPRO. In the same way, the
minimum amount of information needed for each
instrument is difﬁcult to establish.
Conclusions
The EMPRO is a new tool that is available to assess
the measurement properties and ease of use of PRO
measures. Preliminary testing supports its validity
and reliability, but replication of our observations is
needed, using different PRO measures and reviewers. If
these promising results are conﬁrmed, EMPRO should
facilitate the selection of the most appropriate PRO
measure among competing instruments.
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